Dissecting The Rhetoric Vs. Reality Of Trump’s Tough Talk On Drug Prices
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
HHS
501-520 of 559 results
-
-
Timeline: Despite GOP’s Failure To Repeal Obamacare, The ACA Has Changed
A look at the most consequential events that have reshaped the federal health law since President Donald Trump was inaugurated.
By Julie Rovner -
Podcast: KHN’s ‘What The Health?’ Alive And Limping: ACA In The Age Of Trump
In this special episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Alice Ollstein of Talking Points Memo take a deep dive into the state of the federal health law, what happened in 2017 and the Affordable Care Act's viability going forward.
-
Research Misconduct Allegations Shadow New CDC Head
Critics say the Trump administration failed to properly vet Dr. Robert Redfield as they attribute a pattern of “ethically and morally questionable behavior” to him.
-
Podcast: KHN’s ‘What The Health?’ Rocky Road Ahead In Congress For Insurance Market Bills
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post discuss the problems that are making congressional efforts to pass legislation to stabilize the individual insurance market a long shot.
-
No-Go For Idaho: Back To The Drawing Board On State-Based Health Plans
The federal Centers for Medicare & Medicaid Services advised the state that its plan to offer state-based insurance plans falls short of the Obamacare rules and could result in penalties for insurers.
-
Podcast: KHN’s ‘What The Health?’ HHS Leaders Take To The Stump
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and new podcast panelist Anna Edney of Bloomberg News discuss this week’s spate of speeches by the leaders of the Department of Health and Human Services. They also discuss the slow progress on health legislation on Capitol Hill intended to fund the government and stabilize the individual insurance market. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
-
At New Health Office, ‘Civil Rights’ Means Doctors’ Right To Say No To Patients
The HHS civil rights division refocuses on the rights of health care providers who have moral objections to treatments such as abortion or sterilization, alarming critics.
-
Podcast: KHN’s ‘What The Health?’ The Long Wait Ends For Short-Term Plan Rules
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Stephanie Armour of The Wall Street Journal and Julie Appleby of Kaiser Health News discuss the Trump administration’s proposed regulation that would allow the expansion of short-term health insurance policies that do not comply with all the requirements of the Affordable Care Act. The panelists also talk about federal funding (or not) of public health research around guns.
-
In An Effort To Curb Drug Costs, States Advance Bills To Prod Feds On Importation
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
-
Idaho Blue Cross Jumps Into Controversial Market For Plans That Bypass ACA Rules
Focus turns to whether the Trump administration will challenge Idaho’s move to allow such plans to be sold to individuals.
-
Idaho ‘Pushing Envelope’ With Health Insurance Plan. Can It Do That?
Many eyes are on the Trump administration to see how officials respond to Idaho’s approach to health insurance, which flouts some aspects of the Affordable Care Act.
-
Big Pharma Greets Hundreds Of Ex-Federal Workers At The ‘Revolving Door’
A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma’s favor.
-
How The Shutdown Might Affect Your Health
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
-
Trump Administration Clears Way To Force Some Medicaid Enrollees To Work
Allowing states to mandate that non-disabled Medicaid enrollees work as a condition for coverage would mark one of the biggest changes to the program since it began more than 50 years ago. A decision on the first of the state requests could come within days.
-
HHS Nominee Vows To Tackle High Drug Costs, Despite His Ties To Industry
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
-
Grassley Calls For ‘Corrective Action’ On Abuses In Herpes Vaccine Research
The Republican senator sent out letters to the Food and Drug Administration and HHS demanding an explanation about a rogue herpes vaccine trial.
-
Experts Tell Congress How To Cut Drug Prices. We Give You Some Odds.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
-
-
Latest Scandal Too Much For HHS Secretary Tom Price. He’s Out.
Tom Price resigned from running the Department of Health and Human Services after a series of news stories detailing how he tallied more than $400,000 in private plane travel paid for by taxpayers.
By Julie Rovner